CD47 and cancer: CD47 expression leads to reduced phagocytosis by APCs during inflammatory conditions, and finding ways to mitigate this is a valuable strategy to support the development of anti-tumor immune responses prompted by cancer immunotherapies, such as oncolytic NDV.